Duloxetine

證據等級: L5

預測適應症: 10 個

Duloxetine: From Depression and Anxiety to Obsessive-Compulsive Disorder

One-Sentence Summary

Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved internationally for major depressive disorder, generalised anxiety disorder, and chronic pain conditions, though it is not currently registered with Australia’s Therapeutic Goods Administration (TGA). The TxGNN model identifies Obsessive-Compulsive Disorder (OCD) as the highest-evidence predicted indication for repurposing — supported by 5 clinical trials and 20 publications — while noting that the top-ranked TxGNN prediction (benign paroxysmal torticollis of infancy, score 99.85%) carries no supporting evidence and is not suitable for clinical consideration at this stage. Overall evidence for OCD is assessed at Level L3, with a recommendation to Proceed with Guardrails.

Quick Overview

Item	Content
Original Indication	Major depressive disorder / Generalised anxiety disorder / Neuropathic pain (internationally approved; not TGA-registered)
Predicted New Indication	Obsessive-Compulsive Disorder (OCD) — TxGNN rank 3, score 99.84%
TxGNN Prediction Score	99.84%
Evidence Level	L3
Australia Market Status	Not registered in Australia
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank was not included in this evidence pack and will require a supplementary query. Based on well-established published pharmacology, duloxetine is a balanced SNRI that inhibits both the serotonin transporter (SERT) and norepinephrine transporter (NET), increasing synaptic concentrations of both neurotransmitters. It is approved internationally for major depressive disorder, generalised anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain — a broad clinical footprint that reflects its dual neurotransmitter activity.

OCD is characterised by dysregulation of the serotonergic system within the orbitofrontal cortex–striatum–thalamus circuit, driving intrusive thoughts and compulsive behaviours. Serotonin reuptake inhibitors (SRIs) — SSRIs and clomipramine — are the established first-line pharmacotherapy for OCD precisely because of their serotonin reuptake blockade. Duloxetine’s potent SERT binding affinity (Ki ≈ 0.8 nM, comparable to SSRIs) provides a directly analogous and mechanistically coherent rationale for antiobsessional activity, making this TxGNN prediction biologically plausible rather than speculative.

The additional norepinephrine component distinguishes duloxetine from standard SSRIs and may confer specific advantages in treatment-resistant presentations: norepinephrine modulation enhances prefrontal cortex executive control over limbic compulsive circuits, a pathway relevant to refractory OCD. This is supported by clinical evidence including a completed double-blind augmentation RCT, multiple open-label trials, and a body of expert reviews positioning SNRIs as the next-line option when SSRIs and clomipramine have failed.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00464698	Phase 4	Completed	20	Prospective efficacy assessment of duloxetine specifically for OCD — the most directly relevant trial in this evidence pack
NCT01404871	N/A	Completed	26	OCD medication response prediction study; duloxetine included as a designated comparator arm for patients who had previously trialled clomipramine or escitalopram without adequate response
NCT02476136	N/A	Unknown	8,800	Large individual patient data (IPD) meta-analysis examining antidepressant efficacy across anxiety disorder spectrum; OCD may be included in the analysis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27811556	2016	RCT (Augmentation)	J Clin Psychopharmacol	Double-blind controlled trial of duloxetine augmentation in treatment-resistant OCD; the highest-quality direct evidence in this pack
28477500	2017	Meta-analysis	J Affect Disord	OCD demonstrates a reduced antidepressant response compared to other anxiety disorders; important for calibrating expectations and patient selection
32982805	2020	Meta-review	Front Psychiatry	Efficacy and tolerability of antidepressants (including duloxetine) in children and adolescents across OCD, MDD, and anxiety; relevant to paediatric prescribing considerations
25637377	2015	Open-label Trial	Int J Neuropsychopharmacol	Open-label investigation of duloxetine efficacy for DSM-IV OCD; one of the few prospective studies examining duloxetine directly in this indication
31749717	2019	Review	Front Psychiatry	Systematic review of duloxetine use across psychiatric disorders beyond its approved indications, including a dedicated analysis of OCD evidence
24766145	2014	Review	Expert Opin Pharmacother	Updated review of serotonergic antidepressants in OCD; contextualises duloxetine within double-blind study findings across the SRI class
16669725	2006	Review	J Clin Psychiatry	Critical appraisal of SNRIs (venlafaxine and duloxetine) as viable alternatives to SSRIs for OCD treatment
21779536	2011	Review	Innov Clin Neurosci	Positions SNRIs including duloxetine as pharmacological alternatives when first-line OCD treatments (SSRIs and clomipramine) are inadequate
18208931	2008	Case Series	J Psychopharmacol	Case series of patients with SRI-resistant OCD switched to duloxetine; suggests clinical benefit in this difficult-to-treat population
39735048	2024	Case Report	Cureus	High-dose duloxetine combined with CBT achieved full remission in a patient with over a decade of severe treatment-resistant OCD and comorbid MDD

Australia Market Information

Duloxetine is not currently registered with the TGA and has no ARTG entries. No Australian Product Information (PI) documents exist for this drug.

Clinicians wishing to use duloxetine in Australia should consider the TGA Special Access Scheme (SAS Category B) or the Authorised Prescriber pathway. International prescribing information — such as the US FDA-approved label (Cymbalta®) or EMA SmPC — should be consulted for dosing guidance, approved indications, contraindications, and complete safety information pending any future TGA registration.

Safety Considerations

Please refer to relevant international Product Information (e.g., US FDA label or EMA SmPC) for full safety information, as duloxetine has no TGA-approved Australian PI.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Duloxetine’s potent serotonin reuptake inhibition is mechanistically aligned with established OCD pharmacotherapy, and the evidence base — anchored by a completed double-blind augmentation RCT, open-label trials, and multiple systematic reviews — is sufficient to justify further clinical evaluation, particularly for treatment-resistant cases where SSRIs and clomipramine have failed.

To proceed, the following is needed:

Retrieve complete mechanism of action data (SERT/NET binding kinetics, pharmacokinetic profile) from DrugBank API
Obtain full safety data: key warnings, contraindications, and drug interaction profile before any clinical application
Assess serotonin syndrome risk specifically, given concurrent use with other serotonergic agents common in OCD management
Engage the TGA Special Access Scheme (SAS) or Authorised Prescriber pathway, as no Australian registration currently exists
Note that Phase 4 trial NCT00464698 (n = 20) and the augmentation RCT (PMID 27811556) provide the most directly actionable clinical data, but both involve small sample sizes — a prospective Australian case series or registry study would strengthen the local evidence base

⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before therapeutic application. All prescribing decisions must comply with applicable Australian regulatory requirements.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.